Want to see TSE:VIBE full AI Analyst Report?
Vibe Bioscience Ltd (VIBE) AI Stock Analysis
Vibe Bioscience Ltd
(CNQX:VIBE)
Weak financial performance from negative equity and losses is the dominant factor, partially offset by bullish technical momentum while valuation remains unattractive.
Vibe Bioscience Ltd (VIBE) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 680.21K
- Dividend Yield
- ―
- Average Volume (3M)
- 1,781
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 2.41
- Revenue Growth
- 24.29%
- EPS Growth
- 41.04%
- Country
- Canada
- Employees
- 165
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Vibe Bioscience Ltd Business Overview & Revenue Model
Company Description
Vibe Growth Corp. is a vertically integrated cannabis company. The firm operates retail dispensaries, cannabis greenhouse and indoor cultivation, commercial distribution and transportation, e-commerce and home delivery, and manufacturing of marijuana...
Vibe Bioscience Ltd Financial Statement Overview
Summary
Revenue growth to 20.4M and positive operating cash flow of 0.54M show operational progress, but deeply negative equity of -12.2M and net losses create major financial risk.
Income Statement
48NeutralBalance Sheet
18Very NegativeCash Flow
62Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.44M | 17.53M | 12.71M | 14.15M | 20.71M | 29.29M |
| Gross Profit | 7.99M | 6.95M | 4.74M | 5.17M | 6.49M | 8.42M |
| EBITDA | 1.26M | 1.43M | -3.91M | -8.42M | -3.14M | -1.11M |
| Net Income | -3.10M | -2.45M | -6.54M | -11.13M | -9.45M | -4.30M |
Balance Sheet | ||||||
| Total Assets | 15.94M | 10.95M | 11.29M | 16.28M | 25.89M | 32.90M |
| Cash, Cash Equivalents and Short-Term Investments | 1.19M | 753.51K | 1.06M | 1.17M | 4.55M | 9.10M |
| Total Debt | 3.26M | 2.46M | 2.57M | 2.89M | 3.38M | 2.83M |
| Total Liabilities | 28.15M | 18.58M | 16.51M | 15.20M | 13.63M | 11.50M |
| Stockholders Equity | -12.21M | -7.63M | -5.22M | 1.08M | 12.26M | 21.39M |
Cash Flow | ||||||
| Free Cash Flow | 475.19K | 17.18K | 202.82K | -2.78M | -3.71M | -7.20M |
| Operating Cash Flow | 538.97K | 63.61K | 233.74K | -2.71M | -1.97M | 848.73K |
| Investing Cash Flow | -63.78K | -46.43K | 19.02K | -71.80K | -1.75M | -8.43M |
| Financing Cash Flow | -392.84K | -334.53K | -360.37K | -595.55K | -699.14K | 14.33M |
Vibe Bioscience Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VIBE, the sentiment is Positive. The current price of 0.63 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.51, and above the 200-day MA of 0.46, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 67.73 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:VIBE.
Vibe Bioscience Ltd Peers Comparison
Overall Rating
TSE:XBRA48.75Neutral
TSE:VIBE48Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:VIBE | Vibe Bioscience | 0.63 | -0.12 | -16.00% | |
| TSE:MLCL | Molecule Holdings Inc. | 0.01 | 0.00 | 0.00% | |
| TSE:GHG | Global Hemp | 0.02 | 0.00 | 0.00% | |
| TSE:XBRA | Xebra Brands Ltd. | 0.01 | 0.00 | 0.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026